BioSpace News Archive

Mevion Medical Systems announced that Jay S. Loeffler, MD, has been appointed Co-Chair of Mevion Medical Systems Medical/Technical Advisory Board.

Genestack Ltd. announced that its flagship multi-omics data catalog, curation and integrative search product, Omics Data Manager, has been licensed and implemented by a world-leading genomics research centre, the Wellcome Sanger Institute.

Reflects Align’s continued investments in global operations to be closer to its doctor-customers and their patients, enhancing customer experience and satisfaction.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it has received two milestone payments under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.

BioCryst Pharmaceuticals, Inc. announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.

Designed for TLIF procedures, the 3D-printed FORZA Ti Spacer System further expands the comprehensive line of PEEK, PTC, and now Titanium interbody solutions offered by Orthofix for transforaminal lumbar applications

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announces lumateperone presentations at the upcoming American Psychiatric Association (APA) Annual Meeting to be held May 1-3, 2021 and will hold a webcast on May 4, 2021.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.

Kristen Galfetti Appointed as Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President, Finance